Refractory cases unresponsive to antibiotics and DMARDs
Orthopedic referral
Typically after 6 months of failed treatment
Synovial PCR to confirm no active infection before procedure
Active infection should receive further antibiotic course
PCR negative supports surgical candidacy
Antibiotic limitations and contraindications
Agents not recommended
Macrolides (azithromycin) as monotherapy
Higher treatment failure rates
Second-line only with superior options available
Prolonged antibiotic courses
No benefit beyond 8 weeks total including IV
Risk of Clostridium difficile infection
IV antibiotics for post-Lyme syndrome
No objective inflammation markers
Harm without benefit demonstrated in RCTs
Doxycycline contraindications
Pregnancy avoidance
Amoxicillin preferred
Fetal bone and tooth risk
Children under 8 years traditional contraindication
Recent IDSA guidance relaxing restriction for short courses
Risk-benefit assessment per case
Severe esophageal disease or dysphagia
Pill esophagitis risk
Amoxicillin or cefuroxime alternative
Special Populations
Pregnancy
Pregnancy-specific considerations
Antibiotic selection modification
Doxycycline contraindicated in all trimesters
Amoxicillin 500 mg PO three times daily for 28 days preferred
Cefuroxime axetil as alternative
500 mg PO twice daily for 28 days
Safe in pregnancy
IV ceftriaxone for severe or CNS disease
2 g IV daily for 14 to 28 days
Generally considered safe in pregnancy
Fetal and perinatal concerns
No proven vertical transmission in treated mothers
Case reports of congenital Lyme unconfirmed
Treat promptly to minimize any theoretical risk
Obstetric consultation for severe disease
Carditis or neuroborreliosis in pregnancy
Fetal monitoring when viable gestation
Monitoring during treatment
Amoxicillin generally safe in first trimester
Monitor for allergic reactions
Geriatric
Age-related presentation differences
Atypical symptom profile
Delirium as presenting feature of neuroborreliosis
Functional decline as primary complaint
Bimodal incidence peak in 50–64 year age group
High exposure risk from outdoor recreational activities
Less vigorous tick removal behavior
Frailty implications
Lower functional reserve for infection
Polypharmacy drug interaction risk
Medication adjustments in older adults
Doxycycline tolerability
GI upset more common
Take with food and upright posture
Renal function monitoring
Ceftriaxone generally safe but hepatobiliary monitoring
Amoxicillin renal dose adjustment when GFR <30 mL/min
QT prolongation risk assessment
Macrolides and fluoroquinolones higher risk in elderly
Preferred agents do not prolong QT
Differential diagnosis considerations in elderly
Rheumatoid arthritis overlap
Seronegative RA vs Lyme arthritis
Anti-CCP testing
Degenerative joint disease masking Lyme arthritis
Effusion in osteoarthritic knee may be Lyme
Serology essential in endemic area presentations
Pediatrics
Pediatric presentation features
Bimodal age peak at 5–14 years
Highest incidence age group for Lyme disease overall
High outdoor play exposure in endemic areas
Fever more common than in adults
Temperature >38 C during flare
Systemic symptoms more prominent
Monoarticular knee arthritis classic presentation
Often dramatic warm swollen knee
May appear more systemically ill than adult
Antibiotic dosing in children
Doxycycline in children ≥8 years
4.4 mg/kg/day divided twice daily (maximum 100 mg per dose)
Duration 28 days
Amoxicillin in children <8 years or doxycycline intolerance
50 mg/kg/day divided three times daily (maximum 500 mg per dose)
Duration 28 days
Cefuroxime axetil alternative
30 mg/kg/day divided twice daily (maximum 500 mg per dose)
Duration 28 days
IV ceftriaxone for neuroborreliosis or cardiac involvement
50–75 mg/kg/day (maximum 2 g/day)
Duration 14 to 28 days
Juvenile idiopathic arthritis differential
Seronegative Lyme essential to distinguish from JIA
Two-tier serology negative in JIA
ANA and RF testing for JIA
Endemic area context critical for diagnosis
JIA more common outside endemic areas
Pediatric rheumatology consultation for diagnostic uncertainty
Background
Epidemiology
Disease burden and distribution
Most reported vector-borne illness in the United States
Approximately 476,000 cases diagnosed annually in the US
95% of US cases from 14 endemic states
Global distribution
Europe: Borrelia afzelii and B. garinii predominant
North America: Borrelia burgdorferi sensu stricto
Bimodal age distribution
Children 5–14 years
Adults 50–64 years
Late disseminated disease frequency
Approximately 60% of untreated patients develop disseminated disease
Arthritis most common manifestation in North America
ACA predominant in European late disease
Lyme arthritis affects 60% of untreated patients within months to years
Knee involvement in >90% of arthritis cases
Oligoarticular pattern typical
Late neuroborreliosis less common in North America
Encephalomyelitis rare
More common with European Borrelia species
Seasonal and geographic patterns
Peak transmission May through September
Nymphal stage Ixodes scapularis highest risk
Nymphs are small and easily missed
Tick attachment duration 36 to 48 hours required for transmission
Prompt removal reduces risk
Engorged ticks with >36 hours attachment highest risk
Pathophysiology
Borrelia infection mechanisms
Spirochete dissemination from skin
Hematogenous and lymphatic spread
Joint tropism via OspC and other surface proteins
Joint invasion mechanism
Borrelia binds to synovial cells and cartilage matrix
Persists in extracellular matrix
Complement evasion
OspE binds factor H
Serum resistance enables dissemination
Lyme arthritis pathophysiology
Inflammatory synovitis driven by innate and adaptive immunity
Neutrophil-predominant acute phase
T-cell infiltration in chronic synovitis
Post-antibiotic (refractory) Lyme arthritis
Autoimmune mechanism after organism clearance
Molecular mimicry hypothesis
HLA-DR4 associated T-cell reactivity to Borrelia antigens
Synovial cytokine profile
IL-6, IL-17, IFN-gamma elevated
TNF-alpha in active synovitis
Neuroborreliosis pathophysiology
CNS invasion via hematogenous route
Blood-brain barrier disruption
Perivascular inflammation
Intrathecal antibody production
B-cell infiltration of CNS
CSF pleocytosis from immune activation
White matter damage
Vasculitis mechanism
Demyelination in severe cases
Cardiac pathophysiology
AV nodal conduction tissue inflammation
Spirochete invasion of conduction system
Lymphocytic infiltration
Complete heart block self-limited in most cases
Resolution with antibiotic therapy
Permanent pacing rarely required
Therapeutic Considerations
Antibiotic selection rationale
Doxycycline preferred for intracellular penetration
Superior CNS penetration vs beta-lactams
Active against co-infecting Anaplasma
Beta-lactam options for arthritis
Amoxicillin and cefuroxime equivalent efficacy
No CNS penetration advantage for isolated arthritis
IV ceftriaxone reserved for CNS disease and oral failure
Unnecessary for straightforward Lyme arthritis
Risk of hepatobiliary complications with prolonged use
Duration of therapy evidence
28 days for Lyme arthritis based on clinical trials
Shorter courses associated with higher recurrence
No benefit demonstrated beyond 28 days oral
Post-antibiotic Lyme arthritis not responsive to additional antibiotics
RCTs show no benefit from prolonged IV antibiotics
IDSA Class I recommendation against prolonged antibiotics
Two-tiered approach for oral failure
Second oral course or transition to IV ceftriaxone
Rheumatologic management after two adequate antibiotic courses
Immune modulation considerations
NSAIDs as first anti-inflammatory for post-antibiotic arthritis
Reduces synovial inflammation
Low toxicity profile for limited duration
Corticosteroid use caution
May suppress immune response beneficial to spirochete clearance
Reserve for documented post-antibiotic phase
DMARD evidence base
Small case series and expert consensus
Hydroxychloroquine and methotrexate most studied
TNF inhibitors effective in treatment-refractory cases
Patient Discharge Instructions
copy discharge instructions
Lyme disease late stage home care
Antibiotics exactly as prescribed for the full 28 days
Do not stop early even if feeling better
Doxycycline: take with a full glass of water and food
Doxycycline and sun sensitivity
Avoid prolonged sun exposure during treatment
Use sunscreen SPF 30 or higher outdoors
Amoxicillin: take with or without food
Watch for allergic reactions
Rash, hives, or swelling require medical attention
Rest the affected joint if swollen
Gentle range of motion as tolerated
Avoid high-impact activity until swelling resolves
Warning signs to return to the ER immediately
New heart symptoms
Fainting or near-fainting
Irregular or very slow heartbeat
Chest pain or shortness of breath
Worsening neurologic symptoms
Sudden weakness or numbness in limbs
Severe headache with neck stiffness
Facial drooping or double vision
Confusion or difficulty thinking clearly
Joint signs of serious infection
Dramatically increasing swelling, redness, or warmth
Fever above 38.5 C with joint pain
Inability to bear weight
Severe allergic reaction to antibiotic
Difficulty breathing or swallowing
Facial or throat swelling
Widespread rash developing quickly
Follow-up instructions
See your doctor within 1 to 2 weeks after completing antibiotics
Joint swelling should be improving within weeks
If no improvement after full course, do not take extra antibiotics on your own
If arthritis persists after completing treatment
Referral to a rheumatologist expected
Anti-inflammatory medication may be prescribed
Neurologic or cardiac follow-up if applicable
Keep all specialist appointments
Report any new or worsening symptoms
Tick bite prevention
Use DEET or permethrin repellents in outdoor settings
Apply to skin and treat clothing
Reapply as directed on product label
Perform daily tick checks after outdoor exposure
Check all skin folds and hairline
Remove ticks promptly with fine-tipped tweezers
Showering within 2 hours of outdoor activity reduces risk
Inspect clothing before bringing indoors
Tumble dry on high heat to kill ticks on clothes
References
Guidelines and key sources
Primary clinical guidelines
IDSA Clinical Practice Guidelines for Lyme Disease 2006 and 2020 updates
Wormser GP et al. Clinical Infectious Diseases 2006;43:1089–1134
Lantos PM et al. 2021 IDSA Clinical Practice Guidelines
CDC two-tiered testing framework
Modified two-tier testing algorithm
Endorsed for all stages including late disease
ACEP Clinical Policy: Evaluation and Management of Lyme Disease
Level B recommendation for two-tier serology
Level B recommendation for doxycycline oral therapy
Key clinical evidence
Logigian EL et al. Late neurologic Lyme disease. New England Journal of Medicine 1990
Late encephalopathy responds to IV ceftriaxone
Foundational late neuroborreliosis evidence
Klempner MS et al. Two controlled trials of antibiotic treatment. NEJM 2001
No benefit from prolonged antibiotics in post-Lyme syndrome
IV ceftriaxone followed by doxycycline vs placebo
Steere AC et al. Lyme arthritis: overview. Arthritis and Rheumatism landmark series
Established clinical features of Lyme arthritis
Outcome data for treated and untreated cohorts
Diagnostic test references
Eldin C et al. Modified two-tier testing performance
Comparable sensitivity to standard algorithm
Journal of Clinical Microbiology evidence base
PCR sensitivity data for synovial fluid
71–100% sensitivity pre-treatment
Positive post-treatment does not indicate active infection
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.